Abstract
Abstract Liver transplant and resection are preferable for the management of hepatocellular carcinoma, but ultimately, tumor location, biology, and patient condition dictate treatment decisions. At the NCCN 2022 Annual Conference, a panel of experts used 3 case studies to develop an evidence-based approach to the treatment of similar patients with hepatocellular carcinoma. Moderated by Daniel B. Brown, MD, FSIR, the session focused on current research regarding liver-directed and systemic therapy options.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call